The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- (-) Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- NPC News
- Pandemic Response
- (-) Patient Centered Formulary & Benefit Design
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Showing 53 Results
Shared Decision-Making Makes Sense for Patients and the Bottom Line
If shared decision-making is good for patients, is it good for the bottom line as well? A new study from NPC and Real Chemistry sheds light.
Impact of Shared Decision-Making and Patient Decision Aids on Health Care Cost and Utilization in the US: A Systematic Review
Shared decision-making and patient decision aids may reduce costs or improve utilization but not consistently across settings and diseases, according to a new systemic literature review by…
Predictors of Adherence to Oral Anticancer Medications: An Analysis of 2010-2018 U.S. Nationwide Claims
Low-income Medicare patients who face high out-of-pocket costs are less likely to remain adherent to oral anticancer medications. This research shows the need for strategies to address adherence and…
Predictors of Adherence to Oral Anticancer Medications: The Impact of Out-of-Pocket Costs
Biopharmaceutical innovation has led to an increase in the availability of oral anticancer medications (OAMs), but research shows that almost half of patients on OAMs do not take their medications as…
Impact of Real-Time Benefit Tools on Patients’ Access to Medications: A Retrospective Cohort Study
Study finds the use of Real-Time Prescription Benefit Tools results in higher fill rates and lower cancellation rates.
Bringing the Patient Voice Into Benefit Design
Diverse populations have diverse needs, and that's why NPC Chairman Steven Romano says benefit design and coverage policies should start with the patient in mind.
Wage and Its Impact on Access and Adherence to Specialty Medications
Research found that lower-wage employees faced higher out-of-pocket costs, were less likely to use specialty medicines than higher-income workers and relied more regularly on emergency room care.
Specialty Drug and Healthcare Utilization Vary by Wage Level in Employer-Sponsored Health Plans
This research shows that low-wage employees are less likely use autoimmune medicines than employees who earn more despite a higher prevalence of autoimmune conditions in low-wage employees. These…
NPC’s John O’Brien Discusses The Myth of Average on AiArthritis Voices 360 Talk Show
On a recent episode of AiArthritis Voices 360 Podcast, John M. O’Brien discusses NPC’s research on the importance of fostering biopharmaceutical innovation and improving patient access to the right…
Addressing the Needs of People Living With Autoimmune Disorders: A Conversation With Molly Murray
NPC had the opportunity to speak with Molly Murray, president and CEO of the Autoimmune Association, to learn more about the importance of understanding how individual patient differences affect the…
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
The Patient’s Medication Access Journey: A Conceptual Framework Focused Beyond Adherence
The Pharmacy Quality Alliance, with support from NPC, developed a framework that defines a patient’s medication access journey and characterizes barriers frequently encountered while seeking…
Making Our Health Care System More Supportive and Inclusive for Caregivers
NPC President and CEO John M. O'Brien writes about how we can better incorporate the needs of caregivers into our health care system and provide them the support they deserve.
AMCP Partnership Forum: Exploring Paths to Equitable Benefit Design
Mitigating racial health disparities is critical to advancing equitable access to health care, including medications and other therapies. NPC joined other experts at an AMCP Partnership Forum earlier…
Drug Innovations Are Delivering for Patients. We Need Innovation in How They’re Paid For.
In a commentary for PharmaBoardroom, NPC's John M. O’Brien explains why we need a focused effort from all health care stakeholders to innovate on how we pay for vital medicines.
Rethinking Benefit Design: Eliminating Inefficient Hurdles
Reforming health benefits by overhauling existing utilization management practices and adjusting patient cost-sharing to incentivize high-value care would help achieve more affordable, patient…
Why Drug Rebates Aren’t Working for Patients
During a recent webinar, NPC President and CEO John M. O'Brien discusses how the Medicare Part D rebate system creates barriers to affordable care for patients.